+1 (888) 794-0077
« Return
female scientist in lab

White Paper: Managing the Increasing Demands for Scientific Resources During the COVID-19 Pandemic

As our partners’ research and development programs begin to ramp up, so does the need for additional resources. At WuXi AppTec, we remain committed to ensuring the availability and integrity of the research models used on our customers’ vital development programs is maintained—all while ensuring steps are being taken in compliance with disease control guidelines pertaining to COVID-19.

Find out more about how WuXi AppTec is conducting scientific research in a COVID-19 world, providing quality testing support, keeping compounds in China and continuing to move programs forward with a healthy supply of research models.

Receive a copy of our white paper “Conducting Scientific Research in a COVID-19 World: Meeting the Demand for Animal Models”

Related Articles

3 DMPK Strategies for ADC Drugs

3 DMPK Strategies for ADC Drugs

Next-generation AAV (adeno-associated virus) therapies have recently emerged as a significant area of therapeutic innovation to address complex or inherited diseases. They offer a potential pathway to treat conditions once deemed untreatable through methods like replacement, inactivation, or introduction of new materials. Viral vectors are essential for delivering these advanced therapies, as they efficiently transport therapeutic material into target cells. Once inside the cell, the vector incorporates into the host’s natural machinery, enabling protein expression and facilitating treatment outcomes.

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Next-generation AAV (adeno-associated virus) therapies have recently emerged as a significant area of therapeutic innovation to address complex or inherited diseases. They offer a potential pathway to treat conditions once deemed untreatable through methods like replacement, inactivation, or introduction of new materials. Viral vectors are essential for delivering these advanced therapies, as they efficiently transport therapeutic material into target cells. Once inside the cell, the vector incorporates into the host’s natural machinery, enabling protein expression and facilitating treatment outcomes.